Is there a pill version of semaglutide for weight loss?

The FDA approved an oral semaglutide pill for weight loss in December 2025

On December 22, 2025, the U.S. Food and Drug Administration approved oral Wegovy, a once-daily semaglutide 25 mg tablet, for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. Novo Nordisk announced the approval and began making the tablet available at U.S. pharmacies in early January 2026.

This makes oral Wegovy the first oral GLP-1 receptor agonist approved specifically for weight management in the United States. Before this approval, everyone prescribed semaglutide for weight loss used an injectable pen administered once a week. The pill adds a daily oral option under the same Wegovy brand name, with the same FDA-approved indication, including the reduction of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or obese.

The approval is significant because needle-related concerns are among the most commonly cited reasons people hesitate to start injectable GLP-1 therapy. An oral option lowers that barrier for a meaningful share of patients who might otherwise go without treatment.

Oral Wegovy and Rybelsus are both semaglutide pills, but they are not interchangeable

Rybelsus, another oral semaglutide tablet made by Novo Nordisk, has been available since 2019. It is FDA-approved only for blood-sugar control in adults with type 2 diabetes, not for chronic weight management. Its approved doses top out at 14 mg daily, well below the 25 mg maintenance dose in oral Wegovy.

Rybelsus is sometimes prescribed off-label for weight loss, but it does not carry an FDA-approved weight-loss indication. The weight-loss clinical trial data cited in this article was collected at higher doses (50 mg in the OASIS 1 trial and 25 mg in the OASIS 4 trial). The table below shows the key distinctions.

If a provider prescribes Rybelsus for weight loss, that is an off-label use. Oral Wegovy is the appropriate FDA-approved choice for patients seeking a pill specifically for weight management.

Oral semaglutide reaches the bloodstream very differently than an injection

Semaglutide is a peptide, a chain of amino acids that digestive enzymes in the stomach and small intestine would normally break down before it could enter the bloodstream. To get enough drug absorbed through the stomach lining, oral Wegovy tablets use a technology called SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that temporarily changes the local chemistry of the stomach wall to allow a small fraction of the semaglutide to pass into circulation.

Even with SNAC, only about 0.4% to 1% of each dose is absorbed, compared to near-complete absorption from a subcutaneous injection. This low bioavailability is why the oral weight-loss tablet requires 25 mg taken daily to produce effects clinically comparable to 2.4 mg injected once a week: a far greater mass of drug must be swallowed to deliver the same amount to the bloodstream. (Oral Wegovy prescribing information, Clinical Pharmacology section.)

Daily dosing is a direct consequence of this pharmacokinetics. Injectable semaglutide has a half-life long enough to work once weekly; oral semaglutide is cleared more quickly from circulation and requires daily administration to maintain a steady therapeutic level.

Taking oral semaglutide correctly requires strict daily timing

Because oral semaglutide relies on a narrow absorption window in the stomach, the administration rules matter far more than with a typical pill. According to the oral Wegovy prescribing information, the tablet must be taken:

• First thing in the morning, before any food, other beverages, or other oral medications
• With no more than 4 ounces (120 mL) of plain water only (not coffee, juice, or any other liquid)
• At least 30 minutes before the first meal, beverage, or any other oral medication of the day

More water dilutes the SNAC enhancer and raises stomach pH, reducing how much drug crosses the gastric wall. Tablets must be swallowed whole and never chewed or crushed.

Always follow the specific Instructions for Use provided by the dispensing pharmacy and any guidance from the prescribing provider. Never adjust the timing or dose without first speaking with a clinician. For guidance on missed doses, follow the specific Instructions for Use provided with your prescription. Do not double up on doses. Always contact your prescribing provider or pharmacist if you are unsure how to handle a missed dose. For people who drink coffee first thing in the morning, take other medications in the morning, or eat breakfast early, the 30-minute window requires deliberate daily planning. People with irregular schedules may find once-weekly injections easier to fit into their routine than a daily fasting protocol.

The OASIS clinical trials show what oral Wegovy produces for weight loss

The clinical evidence supporting the oral Wegovy approval comes from the OASIS program, a series of phase 3 trials conducted under the named FDA-approved drug Wegovy. These results are attributed to Wegovy specifically. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials.

The OASIS 1 trial, published in The Lancet in 2023, enrolled 667 adults with overweight or obesity (without type 2 diabetes) and tested oral semaglutide 50 mg once daily for 68 weeks. Participants using semaglutide lost an average of 15.1% of body weight versus 2.4% with placebo. Among those taking semaglutide:

• 85% achieved at least 5% weight loss
• 69% achieved at least 10% weight loss
• 54% achieved at least 15% weight loss
• 34% achieved at least 20% weight loss

The OASIS 4 trial, which tested the 25 mg dose used in the approved oral Wegovy tablet, found that participants lost approximately 14% of body weight over 64 weeks of treatment compared to roughly 2% with placebo. Among participants who adhered to the treatment regimen, mean weight loss reached 16.6%. Thirty percent of the semaglutide group achieved at least 20% weight loss, compared to 3% of the placebo group.

Data above are from Wegovy (FDA-approved semaglutide for weight management). Compounded semaglutide is not FDA-approved and these outcomes do not apply to compounded products.

How oral and injectable semaglutide compare on key practical factors

Both oral Wegovy and injectable Wegovy use semaglutide and carry the same FDA weight-management indication. The practical differences come from the route of delivery. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, injectable Wegovy 2.4 mg once weekly produced an average weight loss of 14.9% over 68 weeks. Cross-trial comparisons require caution because the OASIS and STEP trials enrolled somewhat different populations and used different methods, but both show clinically meaningful weight loss in the range of 14% to 16%. All figures in this section are attributed to FDA-approved Wegovy in its respective trial formulation. Compounded semaglutide is not FDA-approved and these outcomes do not apply to compounded products.

For people who can manage a once-weekly routine and are comfortable self-injecting, the injectable form removes the daily fasting window. For people who prefer not to inject, the pill offers a genuine alternative backed by the same FDA-approved indication. To learn more about how semaglutide compares to tirzepatide (another injectable GLP-1/GIP medication), see Semaglutide vs. tirzepatide: what is the difference?

Who may be better served by a pill than a weekly injection

Several groups may find oral Wegovy a better practical fit than the injectable form:

• People with needle phobia or anxiety: Significant fear of needles is common, and for some people it represents a real barrier to starting or staying on injectable therapy. The pill removes that barrier entirely.
• People who prefer a daily routine: Some people find it easier to build medication adherence around a morning pill than to remember and prepare a once-weekly injection.
• People with physical limitations: Certain conditions affecting dexterity or skin can make self-injection difficult or uncomfortable.
• Cost-sensitive patients at starting doses: Through NovoCare Pharmacy, Novo Nordisk's self-pay price for oral Wegovy starting doses (1.5 mg, 4 mg) is lower than the injectable at the same stage.

On the other hand, people who travel frequently, have early-morning schedules that do not accommodate a 30-minute fast, or who already take other morning medications may find the daily fasting protocol more demanding than a once-weekly shot. As of mid-2026, tirzepatide (Zepbound/Mounjaro) is available only as an injection; no FDA-approved oral tirzepatide for weight loss exists.

Understanding what to expect in the first weeks of any GLP-1 therapy helps set realistic expectations. See What should you expect in your first 90 days on a GLP-1? for a week-by-week breakdown.

Side effects of oral semaglutide are mainly gastrointestinal

The most common side effects of oral semaglutide parallel those of injectable GLP-1 medications: nausea, vomiting, diarrhea, and constipation. In the OASIS 4 trial, gastrointestinal adverse events occurred in 74% of the oral semaglutide group compared to 42% of the placebo group, though most were mild to moderate and resolved over time. Only 7% of participants in the semaglutide group discontinued because of adverse events. The ACC journal summary of OASIS 4 notes that nausea rates in the semaglutide arm were 46.6% compared to 18.6% with placebo.

Higher nausea rates with the oral form compared to the injectable are plausible because the tablet contacts the gastric mucosa directly during absorption. Starting at the lowest dose (1.5 mg) and titrating slowly over months is the standard approach to minimizing these effects.

The same rare but serious warnings that apply to injectable semaglutide also apply to oral Wegovy: pancreatitis, gallbladder disease, and a thyroid C-cell tumor signal observed in rodent studies (the significance to humans is not established). People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) should not use semaglutide in any form. A prescribing provider reviews these contraindications before approving treatment. Never start, stop, or change the dose of any medication without guidance from a clinician.

How much oral Wegovy costs in 2026

The out-of-pocket cost of oral Wegovy depends on insurance coverage and the dose. For a full look at GLP-1 costs across all brands, see How much do GLP-1 medications cost per month?

Source: NovoCare Pharmacy price guide. Prices are subject to change; verify current pricing at the time of dispensing. Whether commercial insurance covers oral Wegovy depends on the same plan-level criteria as injectable Wegovy: most plans require documentation of BMI 30 or higher, or BMI 27 or higher with at least one comorbidity, and many require prior authorization.

Compounded oral semaglutide: what patients should know

Compounded oral semaglutide preparations have appeared at some telehealth providers, but the regulatory situation requires careful understanding. Compounded semaglutide in any form, including oral tablets, is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, efficacy, or quality before dispensing. The OASIS trial results discussed in this article apply only to oral Wegovy, the FDA-approved product manufactured by Novo Nordisk.

An additional consideration specific to the oral form: the absorption of semaglutide tablets depends critically on SNAC technology, a specific formulation developed and patented by Novo Nordisk. Because oral bioavailability of semaglutide is already only 0.4% to 1% even with SNAC, small differences in formulation could meaningfully alter how much drug reaches the bloodstream. Whether a compounded oral semaglutide tablet would perform comparably to the clinical trial product has not been studied.

Patients considering compounded semaglutide in any form should discuss the regulatory status, formulation differences, and safety considerations with a licensed provider before making a decision. For a thorough look at what is currently known about compounded semaglutide safety, see Is compounded semaglutide safe?